PDS Biotechnology Corp(PDSB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PDSB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PDS Biotechnology Corp (PDSB), a Healthcare sector company. PDSB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), PDS Biotechnology Corp reports net income of $-7.3M, free cash flow of $-4.4M. Top institutional holders of PDSB by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, BlackRock,, based on the most recent SEC filings. PDSB trades on the Nasdaq exchange and files with the SEC under CIK 1472091. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PDSB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PDS Biotechnology Corp directly from SEC EDGAR.
Net Income
Q1 2026
$-7.3M
Free Cash Flow
Q1 2026
$-4.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+8.3% YoYOperating Income
+13.2% YoYEPS (Diluted)
+28.2% YoYTotal Assets
-32.8% YoYOp. Cash Flow
+20.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-34.5M +8.3% | $-37.6M +12.4% | $-42.9M -5.1% | $-40.9M -141.5% | $-16.9M -141.7% | $-7.0M |
| Operating Income | $-31.5M +13.2% | $-36.3M +15.6% | $-43.0M -3.3% | $-41.7M -94.4% | $-21.4M -1.9% | $-21.0M |
| EPS (Diluted) | $-0.74 +28.2% | $-1.03 +25.9% | $-1.39 +2.8% | $-1.43 -116.7% | $-0.66 | — |
| Total Assets | $30.5M -32.8% | $45.4M -23.6% | $59.4M -22.9% | $77.0M +14.6% | $67.2M +363.7% | $14.5M |
| Operating Cash Flow | $-27.8M +20.8% | $-35.0M -4.1% | $-33.6M -30.8% | $-25.7M -105.9% | $-12.5M +30.9% | $-18.1M |
AI Insight: PDSB Ratio Trends
PDS Biotech remains deeply unprofitable with ROA deteriorating from -55% (Q2 2024) to -99% (Q4 2025), signaling persistent cash burn.
• ROA worsened from -55.1% in Q2 2024 to -99.2% in Q4 2025, indicating accelerating net losses relative to asset base.
• ROE remained severely negative throughout the period, ranging from -107.7% to -195.0%, reflecting consistent shareholder value destruction.
⚠ Q2 2025 ROA (-93.2%) and Q4 2025 ROA (-99.2%) show deterioration trend; monitor if losses stabilize or continue widening.
⚠ OpMargin, NPM, ROIC, and D/E data unavailable; cannot assess profitability path, leverage, or capital efficiency trends.
Get alerted when PDSB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PDS Biotechnology Corp including:
Top Institutional Holders of PDSB
VANGUARD CAPITAL MANAGEMENT LLC
$986.8K1,631,089 shGEODE CAPITAL MANAGEMENT, LLC
$399.5K660,228 shBlackRock, Inc.
$335.2K554,048 shCaption Management, LLC
$193.1K319,100 shVANGUARD FIDUCIARY TRUST CO
$185.9K307,311 shBLAIR WILLIAM & CO/IL
$181.5K300,000 shRENAISSANCE TECHNOLOGIES LLC
$133.6K220,800 shINSPIRION WEALTH ADVISORS, LLC
$110.1K181,995 shARMISTICE CAPITAL, LLC
$105.0K173,605 shSTATE STREET CORP
$80.7K133,333 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $986.8K | 1,631,089 |
| GEODE CAPITAL MANAGEMENT, LLC | $399.5K | 660,228 |
| BlackRock, Inc. | $335.2K | 554,048 |
| Caption Management, LLC | $193.1K | 319,100 |
| VANGUARD FIDUCIARY TRUST CO | $185.9K | 307,311 |
| BLAIR WILLIAM & CO/IL | $181.5K | 300,000 |
| RENAISSANCE TECHNOLOGIES LLC | $133.6K | 220,800 |
| INSPIRION WEALTH ADVISORS, LLC | $110.1K | 181,995 |
| ARMISTICE CAPITAL, LLC | $105.0K | 173,605 |
| STATE STREET CORP | $80.7K | 133,333 |
More Healthcare Companies
View all Healthcare →Put PDSB on your watchlist
Track score changes the day PDS Biotechnology Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PDSB a good stock to buy?
13F Pro's AI-powered analysis of PDS Biotechnology Corp (PDSB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PDSB are available on the PDSB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PDSB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PDSB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PDS Biotechnology Corp's investment landscape.